drugset
drugset / Trial / NCT05518734

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734 ↗

Phase 1 Completed 64 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple ascending doses of VX-708 in healthy participants

Timeline

Start
2022-09-17
Primary completion
2023-03-07
Completion
2023-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-708 Unknown — Intravenous
Background Itraconazole Small molecule — Oral
Background Midazolam Small molecule — Oral

Indications

No indication recorded.